Table 1.
Pediatric liver transplant recipients by weight status at transplant
| Pediatric liver transplant recipients by weight status at transplant, children 6 months–2 yr at transplant
| ||||||
|---|---|---|---|---|---|---|
| Underweight (weight-for-length <5th percentile) | Normal weight (weight-for-length 5th–95th percentile) | Overweight (weight-for-length >95th percentile) | Total | p-value (χ2 or Kruskal–Wallis) | ||
|
|
|
|
|
|
||
| Weight status at transplant | n (%) | n (%) | n (%) | n | ||
| Number | 533 (17) | 2119 (69) | 441 (14) | 3093 | ||
| Female | 287 (17) | 1193 (70) | 221 (13) | 1701 | 0.05 | |
| Male | 246 (18) | 926 (67) | 220 (16) | 1392 | ||
| Age at transplant in months (median, IQR) | 10 (7–13) | 11 (8–16) | 12 (8–18) | 11 (8–16) | 0.0001 | |
| Primary diagnosis | ||||||
| Biliary atresia | 369 (20) | 1312 (70) | 204 (11) | 1885 | <0.0005 | |
| Metabolic disease* | 31 (13) | 166 (68) | 47 (19) | 244 | ||
| Acute liver failure | 10 (6) | 122 (71) | 39 (23) | 171 | ||
| Tumor | 15 (14) | 79 (72) | 15 (14) | 109 | ||
| Other cholestatic conditions† | 72 (14) | 318 (63) | 111 (22) | 501 | ||
| Other‡ | 36 (20) | 122 (67) | 25 (14) | 183 | ||
| Race/ethnicity | ||||||
| White | 282 (17) | 1128 (68) | 238 (14) | 1648 | 0.027 | |
| Black | 112 (20) | 380 (68) | 63 (11) | 555 | ||
| Hispanic | 85 (14) | 432 (70) | 103 (17) | 620 | ||
| Asian | 32 (20) | 102 (64 | 26 (16) | 160 | ||
| Other§ | 22 (20) | 77 (70) | 11 (10) | 110 | ||
| Ethnicity | ||||||
| Hispanic | 95 (15) | 446 (69) | 105 (16) | 646 | 0.069 | |
| Non-Hispanic | 438 (18) | 1673 (68) | 336 (14) | 2447 | ||
| Months of follow-up (median, range) Includes 2380 patients |
68 (24–119) | 67 (23–125) | 67 (23–112) | 67 (24–121) | 0.8331 | |
|
| ||||||
| Pediatric liver transplant recipients by weight status at transplant, children 2–20 yr at transplant | ||||||
|
| ||||||
| Underweight (BMI <5th percentile) | Normal weight (BMI 5th–85th percentile) | Overweight (BMI 85th–95th percentile) | Obese (BMI >95th percentile) | Total | p-value (χ2 or Kruskal–Wallis) | |
|
|
|
|
|
|
|
|
| Weight status at transplant | n (%) | n (%) | n (%) | n (%) | n | |
|
| ||||||
| Number | 321 (7) | 2962 (64 | 751 (16) | 624 (13) | 4658 | |
| Female | 121 (5) | 1469 (61) | 478 (20) | 333 (14) | 2401 | <0.0005 |
| Male | 200 (9) | 1493 (66) | 273 (12) | 291 (13) | 2257 | |
| Age at transplant, yr (median, IQR) | 12.3 (4.6–16.3) | 11.6 (6.7–16) | 10 (5.2–15.7) | 5.7 (3.3–13.3) | 10.7 (5.3–15.8) | 0.0001 |
| Primary diagnosis | ||||||
| Biliary atresia | 42 (5) | 505 (63) | 128 (16) | 132 (16) | 807 | <0.0005 |
| Metabolic disease* | 54 (6) | 571 (67) | 126 (15) | 105 (12) | 856 | |
| Acute liver failure | 51 (6) | 529 (59) | 175 (20) | 138 (16) | 893 | |
| Tumor | 27 (9) | 200 (67) | 30 (10) | 42 (14) | 299 | |
| Other cholestatic conditions† | 74 (10) | 492 (67) | 85 (12) | 80 (11) | 731 | |
| Other‡ | 73 (7) | 665 (62) | 207 (19) | 127 (12) | 1072 | |
| Race/ethnicity | ||||||
| White | 190 (7) | 1855 (66) | 418 (15) | 336 (12) | 2799 | <0.0005 |
| Black | 50 (6) | 461 (58) | 138 (17) | 145 (18) | 794 | |
| Hispanic | 55 (7) | 479 (59) | 153 (19) | 123 (15) | 810 | |
| Asian | 20 (13) | 107 (68) | 19 (12) | 11 (7) | 157 | |
| Other§ | 6 (6) | 60 (61) | 23 (24) | 9 (9) | 98 | |
| Ethnicity | ||||||
| Non-Hispanic | 264 (7) | 2472 (65) | 594 (16) | 499 (13) | 3829 | 0.016 |
| Hispanic | 57 (7) | 490 (59) | 157 (19) | 125 (15) | 829 | |
| Months of follow-up (median, range) Includes 3621 patients |
63 (27–119) | 69 (25–121) | 66 (24–119) | 71 (24–137) | 69 (25–122) | 0.5914 |
Metabolic disease includes: alpha-1-antitrypsin deficiency, Crigler–Najjar syndrome, cystic fibrosis, glycogen storage disease, inborn errors in bile acid metabolism, neonatal hemochromatosis, primary hyperoxaluria, tyrosinemia, urea cycle defects, and Wilson’s disease.
Other cholestatic conditions includes: Alagille syndrome, Byler disease, progressive intrahepatic cholestatic syndromes, total parenteral nutrition cholestasis, sclerosing cholangitis, and idiopathic cholestasis.
Other diagnosis includes: congenital hepatic fibrosis, Budd–Chiari syndrome, autoimmune hepatitis cirrhosis, drug toxicity, hepatitis C cirrhosis, and unknown cirrhosis.
Other race includes: Native American/Alaskan, Pacific Islander/Hawaiian, multiracial, and unknown.